Fosamax for Glucocorticoid-Induced Osteoporosis: Off-Label Use, Evidence, and Monitoring

Is Fosamax (Alendronate) FDA-Approved for Glucocorticoid-Induced Osteoporosis?

Alendronate carries FDA approval for postmenopausal osteoporosis (treatment and prevention), osteoporosis in men, and Paget's disease of bone. Glucocorticoid-induced osteoporosis is not on that list. Using alendronate for GIOP is therefore an off-label application, though it is among the most evidence-backed off-label uses in bone medicine. The ACR, AACE, and Endocrine Society all include it in their GIOP management pathways.

Why Off-Label Does Not Mean Experimental

Off-label prescribing is legal and common in the United States. The FDA approves drugs based on submitted data packages, not on every valid clinical application. Alendronate's manufacturer did not seek a GIOP indication, yet decades of randomized trial data and multiple society guidelines support its use. Physicians at academic medical centers prescribe alendronate for GIOP routinely, and major insurers generally cover it for this indication when documentation of glucocorticoid use is provided.

FDA-Approved Bisphosphonate for GIOP: Risedronate as the Comparator

Risedronate (Actonel) does hold FDA approval for GIOP prevention and treatment in men and women, as does zoledronic acid (Reclast) for GIOP treatment. Alendronate lacks that specific label but performs comparably in head-to-head BMD data. The practical choice between agents often depends on tolerability, cost, and patient preference rather than on the approved-versus-off-label distinction alone.

How Glucocorticoids Damage Bone: The Mechanism That Makes Alendronate Relevant

Glucocorticoids suppress osteoblast differentiation, increase osteoblast and osteocyte apoptosis, and extend osteoclast lifespan, producing a net state of accelerated bone resorption with impaired bone formation [1]. Bone loss is fastest in the first three to six months of glucocorticoid therapy, with lumbar spine BMD declining 6 to 12 percent in the first year at doses above prednisone 7.5 mg/day [2].

The Resorption-Formation Imbalance

Alendronate is a nitrogen-containing bisphosphonate that binds hydroxyapatite at bone resorption sites and inhibits farnesyl pyrophosphate synthase inside osteoclasts. This triggers osteoclast apoptosis and cuts bone turnover markers (serum CTX, urine NTX) by 50 to 70 percent within three months of starting therapy [3]. Because GIOP is driven primarily by excessive resorption in its early phase, an anti-resorptive agent like alendronate is mechanistically appropriate.

Why Bone Turnover Markers Matter in GIOP

Serum C-terminal telopeptide (CTX) and procollagen type I N-terminal propeptide (P1NP) reflect the two sides of bone remodeling. In patients on chronic prednisone, CTX is often disproportionately elevated relative to P1NP, confirming a resorption-dominant state. Tracking these markers at baseline and three to six months after starting alendronate lets the clinician confirm a pharmacological response before the next DXA scan.

The Key Evidence: What Clinical Trials Show

Saag et al. 1998 RCT (N=477): The Landmark Study

The most cited trial on alendronate for GIOP is the Saag et al. Study published in the New England Journal of Medicine. In this 48-week randomized, double-blind, placebo-controlled trial of 477 men and women receiving glucocorticoid therapy, alendronate 5 mg/day produced a 2.1% increase in lumbar spine BMD versus a 0.97% decrease in the placebo group (P<0.001). The 10 mg/day group showed a 2.9% gain (P<0.001) [4]. Femoral neck BMD also improved significantly with both doses.

Cohen et al. 1999 RCT (N=208): Prevention Arm

A companion trial by Cohen et al. (N=208) enrolled patients initiating glucocorticoid therapy within three months and randomized them to alendronate 5 mg/day, 2.5 mg/day, or placebo for 12 months. The 5 mg group preserved lumbar spine BMD (net change +1.7% versus placebo, P<0.001), confirming that early initiation prevents the steepest phase of bone loss [5]. This prevention signal is the basis for guideline recommendations to start therapy within the first 30 days of a new course of prednisone 5 mg/day or more in high-risk patients.

Fracture Data Limitations

Neither the Saag nor Cohen trials were powered for fracture endpoints. Most GIOP trials use BMD as a surrogate. A 2018 Cochrane review of bisphosphonates for GIOP (19 trials, N=2,257) found a significant reduction in vertebral fracture risk with bisphosphonate therapy (RR 0.58, 95% CI 0.38 to 0.88) but noted that the fracture data were derived primarily from risedronate and zoledronate trials rather than alendronate-specific data [6]. Alendronate's anti-fracture efficacy in GIOP is therefore inferred from BMD gains and mechanistic class effects rather than direct fracture endpoint data.

ACR 2022 Guideline Recommendations

The American College of Rheumatology 2022 Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis conditionally recommends oral bisphosphonates (alendronate or risedronate) as first-line agents for most patients requiring glucocorticoid therapy [7]. The recommendation carries a conditional strength with moderate-quality evidence under the GRADE framework.

Which Patients Qualify Under ACR Criteria

The ACR guideline stratifies patients by fracture risk using FRAX and clinical factors:

• High fracture risk: Patients with a prior osteoporotic fracture, T-score at or below -2.5, or a 10-year major osteoporotic fracture probability at or above 20% by FRAX. These patients should start an oral bisphosphonate (or alternatively teriparatide or denosumab) regardless of glucocorticoid dose.
• Moderate fracture risk: 10-year FRAX major fracture probability 10 to 19%, or T-score between -1.0 and -2.5 with age 40 or older on prednisone ≥7.5 mg/day. Oral bisphosphonate is conditionally recommended.
• Low fracture risk: FRAX major fracture probability <10% and T-score above -1.0. Calcium and vitamin D plus lifestyle modification may suffice, with annual reassessment.

The ACR's Direct Language on Bisphosphonates

The 2022 ACR guideline states: "For adults initiating long-term glucocorticoid therapy at any dose who are at moderate or high risk of fracture, we conditionally recommend treatment with an oral bisphosphonate over no treatment." [7] This language applies directly to alendronate as a named agent within that drug class.

Dosing Protocol for Alendronate in GIOP

Standard Weekly Dosing

The standard off-label dosing for GIOP mirrors the FDA-approved dose for postmenopausal osteoporosis: alendronate 70 mg orally once weekly. Some clinicians use the older 10 mg/day daily formulation, which was the dose tested in the Saag 1998 trial, but the weekly 70 mg formulation produces equivalent systemic exposure and is better tolerated from a gastrointestinal standpoint.

Administration Requirements

Alendronate must be taken on an empty stomach with a full 240 mL (8 oz) glass of plain water, at least 30 minutes before the first food, drink other than water, or medication of the day. The patient must remain upright (sitting or standing) for at least 30 minutes after the dose to reduce esophageal irritation. Do not crush or chew the tablet. These instructions apply whether the indication is postmenopausal osteoporosis or GIOP.

Calcium and Vitamin D Co-Administration

Alendronate reduces intestinal calcium absorption acutely around the time of the dose. Calcium supplementation should be taken at a different time of day, not within two hours of alendronate. The ACR guideline and the Endocrine Society both specify 1,000 to 1,500 mg elemental calcium per day (diet plus supplement) and 600 to 800 IU vitamin D per day as a minimum, with many GIOP patients requiring 1,000 to 2,000 IU vitamin D daily to maintain 25-OH vitamin D at or above 30 ng/mL [8].

Monitoring Requirements During Alendronate Therapy for GIOP

Monitoring in GIOP patients on alendronate differs from monitoring in standard postmenopausal osteoporosis because the underlying disease driver (the glucocorticoid) is ongoing and often dose-variable.

Baseline Workup Before Starting

Before initiating alendronate for GIOP, obtain:

1. DXA of the lumbar spine and bilateral hip (total hip and femoral neck)
2. FRAX calculation incorporating glucocorticoid use (check the "secondary osteoporosis" box and consider glucocorticoid-adjusted FRAX if available)
3. Serum 25-OH vitamin D
4. Serum calcium and albumin (to calculate corrected calcium)
5. Serum creatinine and estimated GFR (alendronate is contraindicated when eGFR <35 mL/min/1.73 m²)
6. Complete metabolic panel
7. Serum CTX and P1NP (baseline bone turnover markers)
8. Lateral thoracic and lumbar spine X-ray or VFA (vertebral fracture assessment) if T-score <-1.0 or the patient has lost more than 4 cm of height

DXA Follow-Up Intervals

The ACR 2022 guideline recommends repeat DXA every one to two years while the patient remains on glucocorticoid therapy [7]. This is more frequent than the standard two- to three-year interval used for postmenopausal osteoporosis because glucocorticoid-driven bone loss can be rapid and the risk profile can change substantially if the steroid dose increases or decreases. If the patient achieves stable or improving BMD on a stable steroid dose, some clinicians extend the interval to two years.

Bone Turnover Marker Monitoring

Recheck serum CTX and P1NP three to six months after starting alendronate. A decrease in CTX of 30 to 50 percent from baseline confirms adequate pharmacological suppression of resorption [3]. If CTX does not fall appropriately, consider adherence issues, calcium or vitamin D deficiency, or secondary causes of bone loss such as hyperparathyroidism or malabsorption.

Serum Calcium and Vitamin D Surveillance

Recheck 25-OH vitamin D and serum calcium at three months, then every six to twelve months. Glucocorticoids impair renal 1-alpha-hydroxylation of vitamin D and reduce intestinal calcium absorption, so deficiency is common and can undermine alendronate's efficacy [8]. Maintain 25-OH vitamin D at 30 to 50 ng/mL throughout therapy.

Kidney Function Reassessment

Recheck eGFR annually. If eGFR falls below 35 mL/min/1.73 m², discontinue alendronate and discuss alternatives (denosumab does not require dose adjustment for renal impairment; teriparatide and abaloparatide are options in severe cases).

Safety Considerations Specific to GIOP Patients

Gastrointestinal Risk

Glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs) both increase gastrointestinal mucosal injury. Alendronate carries its own esophageal and gastric risk. Patients on chronic prednisone who also need alendronate should be screened for dyspepsia, GERD, and active esophageal disease before prescribing. If active upper GI pathology is present, intravenous zoledronic acid 5 mg once yearly is a reasonable alternative that avoids the esophageal exposure entirely [9].

Osteonecrosis of the Jaw (ONJ)

ONJ risk with oral bisphosphonates at osteoporosis doses is low, estimated at 1 in 10,000 to 1 in 100,000 patient-years [10]. Glucocorticoid use is itself an independent risk factor for ONJ, which means GIOP patients may carry a modestly higher baseline ONJ risk. Advise patients to complete any necessary dental procedures before starting alendronate, maintain good oral hygiene, and report jaw pain or nonhealing oral wounds promptly.

Atypical Femoral Fracture (AFF)

Long-term bisphosphonate use (generally beyond five years) is associated with atypical subtrochanteric or diaphyseal femoral fractures. The absolute risk is low (3 to 50 per 100,000 person-years depending on duration of use) [11]. Ask about thigh or groin pain at every clinic visit after three years of continuous alendronate use. A prodromal pain syndrome often precedes complete fracture by weeks to months. If AFF is suspected, bilateral femur X-rays should be obtained immediately.

Drug Holidays in GIOP

The standard bisphosphonate drug holiday concept (suspending therapy after five years in low-risk patients) applies differently in GIOP. If the patient remains on glucocorticoids, the active bone-loss driver persists, and a drug holiday is generally not appropriate. Drug holidays can be considered only if glucocorticoid therapy has been discontinued and BMD has stabilized. The ACR 2022 guideline addresses this nuance directly [7].

Special Populations

Premenopausal Women

Premenopausal women requiring long-term glucocorticoids represent a particularly complex group. Alendronate is FDA-approved only in postmenopausal women, and its use in premenopausal women is off-label within the off-label GIOP use. The ACR guideline conditionally recommends oral bisphosphonates in premenopausal women at high fracture risk, with the caveat that teratogenicity data for bisphosphonates are limited and that women of childbearing potential should use reliable contraception during therapy [7]. If pregnancy is planned within the next two years, teriparatide or close monitoring without pharmacotherapy may be preferable.

Older Men on Glucocorticoids

Men over 50 on chronic prednisone are at substantial fracture risk yet are often undertreated. The Saag 1998 trial included men, and alendronate 10 mg/day produced a 2.9% lumbar spine BMD gain in men over 12 months [4]. The ACR recommends the same risk-stratification and treatment approach for men as for women.

Transplant Recipients

Solid organ transplant recipients often receive high-dose glucocorticoids for months to years. Bisphosphonate therapy in this population may need to be deferred immediately post-transplant due to renal instability, but initiation within six to twelve months post-transplant is common practice when eGFR stabilizes above 35 mL/min/1.73 m² [12].

Alendronate Versus Other GIOP Agents: A Clinical Comparison

| Agent | Route | FDA-Approved for GIOP | Typical Dose | Key Advantage | |---|---|---|---|---| | Alendronate (Fosamax) | Oral | No (off-label) | 70 mg/week | Low cost, generic available | | Risedronate (Actonel) | Oral | Yes | 35 mg/week or 150 mg/month | FDA-approved for GIOP | | Zoledronic acid (Reclast) | IV | Yes (treatment) | 5 mg/year | Annual dosing, no GI issues | | Teriparatide (Forteo) | SC injection | Yes (treatment) | 20 mcg/day | Anabolic; preferred in very high-risk patients | | Denosumab (Prolia) | SC injection | No (off-label) | 60 mg every 6 months | No renal dose limit | | Abaloparatide (Tymlos) | SC injection | No (off-label) | 80 mcg/day | Anabolic alternative to teriparatide |

The cost argument favors alendronate. Generic alendronate 70 mg tablets cost approximately 10 to 20 dollars per month at most pharmacies, while zoledronic acid infusions may cost 200 to 1,000 dollars per year after insurance. For patients without upper GI disease or severe renal impairment, alendronate remains the pragmatic starting point.

When to Refer to an Endocrinologist or Rheumatologist

A specialist referral is appropriate when:

• BMD continues to decline despite 12 months of adherent alendronate therapy
• FRAX score places the patient in the very high fracture risk category (10-year hip fracture probability ≥4.5% with additional clinical risk factors per NOF criteria)
• The patient has an eGFR <35 mL/min/1.73 m² requiring alternative therapy
• Secondary causes of bone loss remain undiagnosed after baseline workup
• The patient is premenopausal and planning pregnancy
• An atypical femur fracture is suspected